James Glover has been named CEO of Beckman Coulter, having served as the company’s interim CEO since Aug. 2003.

Glover joined Beckman Coulter in 1983. Since the beginning of 2003, he has served as vice president, controller, and chief accounting officer. While at the company, he has led its capital restructuring and elimination of over $450 million in debt, as well as its risk management program and other efforts related to bond ratings and tax rate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Futurism writes that gene doping could be the next generation of cheating in sports.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.